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Abstract:   
Intraperitoneal and catheter exit site infections are the most common complications 
associated with prolonged peritoneal dialysis (PD) therapy used for treating the 
patients with end stage renal failure (ESRF). Recurrent and persistent infections often 
cause inflammation of the peritoneum, a condition known as infectious peritonitis and 
to resolve the condition, patients require antibiotic treatment. However, if the 
treatment is delayed or if it fails due to antibiotic resistance, the peritonitis may lead to 
permanent malfunctioning of peritoneal membrane causing technique failure and 
transferring the patients to haemodialysis. Severe and prolonged peritonitis is not only 
the major cause of technique failure, it is also the leading cause of mortality and 
morbidity in PD patients. Therefore, there is an urgent need to improve the existing PD 
technique so that the frequency of PD associated infections could be reduced and 
infectious peritonitis episodes thereof during prolonged peritoneal dialysis. In this 
perspective, I highlight the possibility to improve the PD technique through the use of 
antimicrobial nanoparticles synthesized biologically.  
Perspective  
Peritoneal dialysis (PD) is a well-established renal replacement therapy (RRT) used for treating 
patients with end-stage renal failure (ESRF) [1,2] (Fig. 1A). It is highly cost-effective and offers 
certain clear advantages over haemodialysis (HD) such as simplicity, flexible lifestyle, reduced 
need for trained technicians and nurses, minimal technical support requirement, lack of 
electricity dependence, and home-based therapy [1,3-5]. Compared to HD, it also provides 
stable hemodynamics and better preservation of residual renal function [1,3-5]. Though PD has 
potential cost savings and offers several advantages over HD [6], however, it is often 
associated with a high risk of infection of the intraperitoneal cavity, subcutaneous tunnel and 
catheter exit site and subsequently formed microbial biofilms. After cardiovascular disease, 
infection is the second leading reason for admission to hospital among patients receiving 
long-term dialysis [7]. Mostly, the PD patients suffer from bacterial and fungal infections. 
Bacterial infections generally develop from colonization of sporadic microbial contaminations 
either through the stomach or through the catheter exit site and fungal infections may 
develop subsequent to antibiotic use. In most of the cases, the infections resolve through the 
use of empiric anti-biotic treatment. The prescribed anti-biotic treatment is well justified if the 
infections appear occasionally. However, ESRF patients continuing on PD generally suffer from 
inherently weak and sabotaged immune system; therefore the infections are as frequent as 
once after every 10-15 weeks. However, the major drawback associated with frequent use of 
conventional antimicrobial agents is the development of multiple drug resistance. Drug 
resistance enforces high antibiotic dose administration which may cause intolerable toxicity or 
adverse side effects. 
Further, if the infections sustain for a week or more (either because of delayed treatment or 
multidrug resistant pathogens), these may lead to the inflammation of the peritoneum or 
abdominal cavity lining, the condition commonly known as infectious peritonitis [8,9]. The 
condition severely affects the functioning of peritoneal membrane and to resolve the 
condition, patients require hospitalization which not only poses financial burden on such 
patients because of higher medical costs, but, also poses a burden on nephrology wards for 
admitting such patients. Established treatment of infectious peritonitis involves rapid resolution 
of inflammation by eradicating the causative organism(s) and preservation of peritoneal 
membrane function. In severe cases, the intravenous antibiotics may become necessary. 
However, sometimes, even after the use of intravenous and intraperitoneal antibiotics, the 
treatment may fail to resolve the infectious peritonitis and the patients are transferred to 
haemodialysis (HD), either temporarily or permanently; thus reducing patient’s autonomy and 
increasing hospitalization [2,9].  
Figure 1: (A) Pictorial representation of peritoneal dialysis procedure and (B) schematic showing the 
generalized mechanism of biocides activity of AM nanoparticles (the microbial components or sites 
targeted by NPs are highlighted here using yellow sparks) in addition to illustrating their use for 
developing infection resistant PD fluid composition. In (A) and (B), the acronyms AM, NP, NAPs and MTS 
represent, respectively, anti-microbial, nano-particle, nuclear associated proteins and membrane 
transport system.  
Infectious peritonitis is not only the major cause of technique failure, but it is also the 
leading cause of mortality and morbidity in PD patients. Around 18% of the infection-related 
mortality in PD patients is the result of peritonitis [2,9,10]. Although less than 4% of peritonitis 
episodes result in death, it is a “contributing factor” to death in 16% of deaths on PD [9]. 
Statistically, about 60-70 deaths per 1000 PD patients are seen every year and the proportion is 
higher in developing countries where majority of the patients belong to families of low 
socioeconomic status [11-13]. As the number of ESRF patients continuing on PD is increasing 
every year (because of unavailability of kidneys required for the transplantation and various 
other limitations) and majority of them remain on PD for more than a year, therefore in near 
future, the infectious peritonitis is going to be one of the most serious healthcare associated 
complications [14,15]. According to an estimate, for every 0.5 increase in peritonitis rate per 
year, the risk of death increases by 4 % [13]. The above statistical figures, clearly highlight the 
public health importance of improving the existing PD technique in terms of its efficacy and 
adequacy to limit infections during long-term PD; so that the traumatic and life-threatening 
episodes of infectious peritonitis can be reduced [8,9]. Practically, this can be achieved 
through developing infection resistant PD fluid composition which provides long term 
protection against variety of PD associated infections including bacteria, mycobacteria, fungi 
or viruses. And, the key requisite to develop such an efficient and novel composition is that the 
composition should contain some antimicrobial agents with novel (non-antibiotic) mode of 
action to avoid the problems arising because of antibiotic resistance. Further, these 
antimicrobial agents should preserve their efficacy and adequacy (i.e. biocompatibility and 
non-cytotoxicity) during long-term intraperitoneal use.  
In the above context, antimicrobial nanoparticles (AM-NPs) -especially, the metal and 
metal oxide NPs- would be of potential interest owing to their exclusive antimicrobial activity 
against variety of clinical infections [16-20] wound healing [21-23] and anti-inflammatory 
properties [24,25]. These NPs have been researched extensively in the past and some classes 
of metal (e.g. Gold, Silver, Titanium, Bismuth etc.) and metal oxide (e.g. zinc oxide, titanium 
oxide, etc.) nanoparticles have been found to be very effective in terms of their antimicrobial 
properties [26-30] and anti-biofilm properties [31,32]. Most importantly, these NPs produce their 
antimicrobial (AM) activity through affecting multiple biological pathways (Fig. 1B) found in 
microbial species and many concurrent mutations would have to occur in order to develop 
resistance against antimicrobial activity of these NPs [19]. Therefore, as required to manage 
recurrent and persistent infections during long-term PD, these NPs can be used frequently 
without posing any risk of developing antibiotic resistance. Studies have also demonstrated 
that naturally occurring bacteria do not develop antimicrobial resistance to metal NPs [18]. 
Some classes of metallic NPs have potential to eradicate multidrug-resistant infections  when 
used in combination with antibiotics (synergic-effect) [18,19]. Like-wise, some classes can limit 
biofilm formation either independently [31,32] or when used in combination with antibiotics 
(through synergic effect) [16]. Owing to such broad spectral antimicrobial properties and 
activity against biofilms and formidable multidrug resistant pathogens, metallic nanoparticles  
are finding their potential applications as antimicrobial agents and disinfectants to improve 
several biomedical devices, pharmaceutical products and healthcare interventions including 
medicines [16,18,19,26,33].  
Metallic nanoparticles of varying sizes, shapes, and properties can be synthesized using 
variety of chemical and physical methods [28,34-36]. However, these methods are neither 
cost-effective nor eco-friendly and further lead to the presence of some toxic chemicals 
adsorbed on the surface that could produce intolerable toxicity to humans and adverse 
effects in biomedical applications [34,37-40]. This is not an issue when it comes to biologically 
synthesized nanoparticles i.e. those synthesized from biomaterials derived from micro-
organisms or plant parts following green chemistry approach  [41-43]. Biological synthesis of 
NPs is considered as environmentally benign replacement to the toxic chemical and physical 
methods and studies have shown that biogenic NPs exhibit benign pharmacology response 
(i.e. better biocompatibility and less cytotoxicity) compared to their counterparts prepared 
using physical and chemical methods [44-47]. A recent study has shown that biogenic Zinc 
oxide NPs exhibit significantly higher biocidal activity against various pathogens when 
compared to chemically synthesized ZnO nanoparticles. Such preliminary studies  are clearly 
suggesting that biogenic NPs have huge potential to address future medical concerns [34].  
Biological synthesis of nanoparticles is gaining tremendous popularity owing to its cost-
effectiveness, simplicity and eco-friendliness [34,37,38,40,43,48-52]. However, biological 
synthesis of nanoparticles using microorganisms has been found to be more tedious and time 
taking process as it requires more steps in maintaining cell culture, longer incubation time for 
the intracellular reduction of metal ions and more purification steps. On the other hand, the 
plant mediated green synthesis of nanoparticles is relatively simple and provides several clear 
advantages like (a) avoidance of maintaining time-consuming  microbial  cultures and 
purification steps, (b) rapid extracellular biosynthesis as water soluble phytochemicals reduce 
the metal ions in a much lesser time, (c) safe to handle and cost effective and (d) availability 
of broad variability of metabolites that may aid in reduction [52] [34,36-39,43,49-51]. The 
generalized flow chart for plant mediated nano-biosynthesis is shown in Figure 2 
schematically.  
 
Figure 2: Flowchart denoting the plant-mediated biological synthesis of nanoparticles. 
 
Recently, immense applications of biogenic metal NPs have been envisaged in various 
biological and clinical settings [45-47,53-55]. Here, I envisage that biogenic metal NPs can also 
be used to attribute infection resistant properties to peritoneal dialysis fluid. However before 
putting these biogenic nanomaterials into human healthcare actions, the key step is to rule 
out their nano-toxicity and adverse effects on long-term exposure. For this, conscience efforts 
are required to evaluate their pharmacology through conducting dose and time of exposure 
dependent ex vivo and in vivo studies on human cell lines and animal models. After successful 
evaluation of preclinical efficacy and toxicity, the promising biogenic nanoparticles -with 
efficient antimicrobial properties and exhibiting favorable in vivo pharmacology response- 
can be envisaged to develop infection resistant composition of peritoneal dialysis (PD) fluid.  
Simply, this will be achieved through adding non-toxic doses of biogenic NPs into different 
types of PD fluids widely used in clinics and subsequently, evaluating (a) their efficacy against 
variety of healthcare associated infections, (b) in vivo adequacy, and (c) time stability to 
ensure their long-term storage and prolonged shelf life. The particular advantage of 
employing biogenic AM-NPs in this translational research endeavor is that these can be filter-
sterilized and added directly to the PD fluid for long term storage and  prolonged shelf life [56]. 
Further, these can easily withstand temperature variations (ranging from 4 to 50 C which is 
generally encountered during transportation and storage of medical products), under which 
conventional antibiotics may inactivate or degrade. Moreover, the preparation of 
nanoparticles is cost-effective and relatively simple compared to antibiotics synthesis. These 
were the potential advantages which derived my interest to write this perspective to highlight 
the use of biogenic nanomaterials for developing infection resistant composition of PD fluid.  
In conclusion, necessity to improve the PD technology for limiting frequent PD associated 
infections and possibility to encompass the benefits of AM-NPs synthesized biologically, have 
been discusses here. Particularly, the biocompatibility and cytotoxicity of biogenic AM-NPs are 
the key issues to be addressed before putting them into clinical applications. Further, the use 
of novel AM-NPs in combination with novel antibiotic agents can also be explored to manage 
multidrug resistant pathogens and formation of biofilms during long-term PD. The antibiotics 
can be added directly into the PD fluid at the time of intraperitoneal instillation or through 
nano-drug carriers to facilitate their slow and sustained release. I foresee that the research 
perspective presented here will definitely appeal some of the biomedical and clinical 
researchers (involved in developing, implementing, and evaluating infection prevention and 
control programs for healthcare settings) to put their conscience efforts in the direction to 
develop infection resistant PD fluid composition or nanotechnology based solutions targeting 
biofilms for efficient and long-term management of peritoneal dialysis. The improvisation will 
help the PD patients in two ways: (a) first it will provide them a better quality of life through 
reducing the frequency infectious peritonitis and (b) second it will reduce the financial burden 
on such patients through reducing medical costs and their visits to hospitals. Other major 
problem associated with long-term PD is the recurrent and persistent infections on the 
catheter exit site as it remains constantly exposed to the non-sterile environment outside the 
body. Therefore, efforts are also required to make the catheter exit site sterile through 
covering it with smart antimicrobial gels providing long-term protection without posing any risk 
of antibiotic resistant. 
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